PreludeDx™ Announces New Contract with MediNcrease Health Plans for its Novel DCIS Test, DCISionRT®
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it...
Source: prnewswire.com